基于蛋白质-类复合物的盐塑料,在胃肠道药物输送中固定有机分子,用于治疗性结肠炎
Liang Guo1, Ge-Ge Zheng1, Rong-Yi Li1
1School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing 210023, China.
International journal of biological macromolecules
|October 2, 2024
概括
这项研究开发了Saloplastics (SAL),一种用于治疗性结肠炎 (UC) 的新型药物输送系统. 盐酸有效地提供异氨酸 (ISO),减少炎症并延长剂量间隔,以获得持续的缓解.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,需要有效的治疗策略.
- 目前对UC的治疗方法通常涉及频繁的剂量,并且可能有局限性.
- 开发新的药物输送平台对于改善UC治疗结果至关重要.
研究的目的:
- 开发和评估一个持续释放药物递送平台,Saloplastics (SAL),用于治疗DSS诱导的大肠炎.
- 在SAL中封装异氨酸 (ISO),以提高治疗效果.
- 研究SAL的物理化学和生物特性,用于口腔胃肠道应用.
主要方法:
- 使用 kazeinate (SC) 和 ε-polylysine (EPL) 制造多电解质复合物 (PEC),以形成SAL.
- 使用分子动力学模拟和实验方法,对SAL的结构,物理化学特性 (热塑化,胀,水解) 和形态的表征.
- 在DSS诱导的大肠炎的小鼠模型中对ISO@SAL进行体内评估,以评估治疗疗效和剂量间隔.
主要成果:
- 盐酸自组装成类似纳米的结构,由疏水聚合和静电吸引驱动.
- 在模拟的胃液中,SAL表现出热塑性,优异的膨胀能力和易于水解的易感性.
- ISO@SAL在缓解DSS诱导的大肠炎方面表现出显著的功效,并允许从一到三天的剂量间隔延长.
结论:
- 盐塑料 (SAL) 是一种生物相容,持续释放的口服药物递送平台.
- 盐酸盐在胃肠道应用方面表现有前途,特别是在治疗性结肠炎等炎症状况方面.
- 开发的平台通过延长剂量间隔,提高了药物递送效率和患者的遵守性.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
128
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
128
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
372
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
372
01:21Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
409
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
409
01:20Drugs Affecting GI Tract Motility: Other Laxatives
172
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
172
01:17Drugs for Treatment of Diarrhea-Predominant IBS
151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151